The Trump administration just slammed the brakes on a major Biden-era push: expanding Medicare and Medicaid coverage for obesity drugs like Wegovy (semaglutide) and Zepbound (tirzepatide)
Gastrointestinal effects of GLP-1 agonists
Peripherally acting anti-obesity medicines with evidence for use in older adults Orlistat Weight loss trials None of the XENDOS trial participants were older adults, and hence the results from this study may not be applicable to an ageing population, although as the drug works peripherally there is no reason to suggest reduced efficacy or safety in elderly patients
GCG activation suppresses endogenous hepatic lipid production by inhibiting lipogenic enzymatic pathways while simultaneously enhancing mitochondrial oxidative lipid catabolism, thereby promoting lipid catabolism and reducing hepatic triglyceride content [18]
"Now that GLP-1based therapies have been shown to increase the risk of pancreatic inflammation and abnormal cell proliferation, further studies are needed to urgently clarify whether these linkages lead to pancreatic cancer with long-term use." Study co-authors, in addition to Butler and Atkinson, are Alexandra E
For many patients, this initial phase of adjustment is temporary and manageable with a few simple strategies: Eat Small, Frequent Meals : Large meals can overwhelm your GI system
